Symbol | Exchange | Currency |
|---|
NEW YORK (Reuters) - Retail investors have been among those selling shares in Didi Global, which tumbled after the ride-hailing company revealed its plan to withdraw from the New...
By Lewis Krauskopf NEW YORK (Reuters) - The emergence of Omicron is fueling uncertainty in markets, as investors await information about the heavily mutated coronavirus variant...
A look at the day ahead from Danilo Masoni. Sell first, get answers later. With stocks near lifetime peaks, the Black Friday reaction to the new fast-spreading virus strain...
Investors prick up their ears to front-run the Fed’s taper. It looks like a tricky game though, given its contradictory statements. What’s the truth?You Don't Say!At...
Vanda (NASDAQ:VNDA) Pharmaceuticals (VNDA) shares soared 5.8% in the last trading session to close at $21.51. The move was backed by solid volume with far more shares changing...
Menlo Therapeutics Inc. (NASDAQ:MNLO) announced that it has completed patient enrollment in its phase II study evaluating the safety and efficacy of once-daily oral serlopitant...
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 171.18 | 171.58 | 168.34 | +5.86 | +3.54% | 111.37M | NASDAQ | |||
| 2,945.40 | 2,950.60 | 2,905.00 | +82.3 | +2.87% | 1.56M | NASDAQ | |||
| 322.81 | 326.54 | 321.00 | +4.94 | +1.55% | 17.34M | NASDAQ | |||
| 204.37 | 206.21 | 203.07 | +3.09 | +1.54% | 2.59M | NYSE | |||
| 61.52 | 62.38 | 60.70 | +1.68 | +2.81% | 13.88M | NYSE | |||
| 416.26 | 418.51 | 413.02 | +0.56 | +0.13% | 3.94M | NYSE | |||
| 324.27 | 324.49 | 306.51 | +23.90 | +7.96% | 58.43M | NASDAQ | |||
| 51.74 | 52.50 | 50.41 | +0.26 | +0.51% | 34.58M | NYSE | |||
| 125.54 | 129.45 | 123.46 | +1.94 | +1.57% | 38.38M | NYSE | |||
| 3,523.29 | 3,549.99 | 3,466.69 | +95.92 | +2.80% | 3.23M | NASDAQ | |||
| 177.96 | 181.97 | 170.65 | +10.84 | +6.49% | 1.93M | NYSE | |||
| 13.63 | 14.06 | 13.55 | +0.24 | +1.79% | 55.38M | NYSE | |||
| 52.57 | 55.00 | 52.21 | +1.58 | +3.10% | 89.33M | NASDAQ | |||
| 67.23 | 67.65 | 66.55 | +1.16 | +1.76% | 5.58M | NASDAQ | |||
| 282.35 | 287.77 | 263.07 | +17.02 | +6.41% | 10.58M | NASDAQ |